Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dextromethorphan and quinidine Clear all
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT02442765
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
111
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients

NCT00050232
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 68 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
20
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

NCT01584440
View directory record Official record
Conditions
Agitation, Alzheimer's Disease
Interventions
AVP-923-20, Placebo, AVP-923-30
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 3 Interventional

Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

NCT00021697
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
17
States / cities
Loma Linda, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease

NCT03854019
View directory record Official record
Conditions
Huntington Disease, Irritability
Interventions
Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg), Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 23, 2026, 8:15 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition

NCT02534038
View directory record Official record
Conditions
Disinhibition Syndrome
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

NCT02442778
View directory record Official record
Conditions
Agitation in Participants With Dementia of the Alzheimer's Type
Interventions
AVP-786-18, Placebo, AVP-786-28, AVP-786-42.63
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 3 Interventional

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

NCT00056524
View directory record Official record
Conditions
Alzheimer's Disease, Stroke, Parkinson's Disease, Traumatic Brain Injury
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
39
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 23, 2026, 8:15 PM EDT
Terminated Phase 4 Interventional Results available

Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)

NCT02496039
View directory record Official record
Conditions
Pseudobulbar Affect (Involuntary Laughing and/or Crying)
Interventions
NUEDEXTA®
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • Centerville, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

NCT01767129
View directory record Official record
Conditions
Dyskinesia, Parkinson's Disease
Interventions
AVP-923-45, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants

NCT03381664
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Nuedexta in Treatment-Resistant Major Depression

NCT01882829
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant
Interventions
dextromethorphan/quinidine
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

NCT05444556
View directory record Official record
Conditions
Healthy
Interventions
Imlunestrant, Repaglinide, Omeprazole, Dextromethorphan, Quinidine, Rosuvastatin, Digoxin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
3
States / cities
Cypress, California • South Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Nuedexta for the Treatment of Adults With Autism

NCT01630811
View directory record Official record
Conditions
Autism
Interventions
Nuedexta, Placebo
Drug · Other
Lead sponsor
Sutter Health
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

NCT01324232
View directory record Official record
Conditions
Central Neuropathic Pain, Multiple Sclerosis
Interventions
AVP-923-45, AVP-923-30, AVP-923-20, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
44
States / cities
Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Comparing AVP-786 With AVP-923

NCT02336347
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AVP-786, AVP-923
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Terminated Phase 4 Interventional

Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease

NCT01832350
View directory record Official record
Conditions
Alzheimer's Disease, Pseudobulbar Affect (PBA)
Interventions
Nuedexta (20/10)
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
55 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts

NCT02402595
View directory record Official record
Conditions
Healthy
Interventions
AVP-923, AVP-786, Itraconazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT02153502
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 23, 2026, 8:15 PM EDT
Terminated Phase 3 Interventional Results available

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT02446132
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
171
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial Nuedexta in Subjects With ALS

NCT01806857
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Nuedexta, Matching Placebo
Drug
Lead sponsor
Center for Neurologic Study, La Jolla, California,
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine

NCT02176018
View directory record Official record
Conditions
Episodic Migraine
Interventions
Dextromethorphan and quinidine, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Rockford, Illinois • Ridgeland, Mississippi • City of Saint Peters, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS

NCT00573443
View directory record Official record
Conditions
Pseudobulbar Affect (PBA)
Interventions
dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
45
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 23, 2026, 8:15 PM EDT
Completed Phase 4 Interventional Results available

Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)

NCT01799941
View directory record Official record
Conditions
Pseudobulbar Affect (PBA), Stroke, Dementia, Traumatic Brain Injury (TBI)
Interventions
Nuedexta (DM 20 mg/Q 10 mg)
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pensacola, Florida
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 23, 2026, 8:15 PM EDT